Meglumine antimoniate

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Meglumine antimoniate
Meglumine antimoniate major component 3D.png
Systematic (IUPAC) name
Hydroxy-dioxostiborane; (2R,3R,4R,5S)-6-methylaminohexane-1,2,3,4,5-pentol
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
Identifiers
CAS Number 133-51-7 N
ATC code P01CB01 (WHO) QP51AB01 (WHO)
PubChem CID 64953
ChemSpider 58479 YesY
UNII 75G4TW236W YesY
ChEMBL CHEMBL239129 YesY
NIAID ChemDB 008733
Chemical data
Formula Variable
Molar mass Variable
 NYesY (what is this?)  (verify)

Meglumine antimoniate (or meglumine antimonate) is a medicine used for treating leishmaniasis.[1] It is manufactured by Aventis[2] and sold as Glucantime in France, and Glucantim in Italy. It belongs to a group of compounds known as the pentavalent antimonials. It is administered by intramuscular injection.

See also[edit]

References[edit]

  1. ^ Soto, J.; Fuya, P.; Herrera, R.; Berman, J. (1998). "Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: Controlled study". Clinical Infectious Diseases. 26 (1): 56–58. doi:10.1086/516267. PMID 9455509. 
  2. ^ Aventis press release, 15 April 2005. (German)